Bausch + Lomb outlines 2026 revenue target of $5.475B with margin expansion driven by dry eye growth
Source: SeekingAlpha
2026-02-18 12:56:09 ET
More on Bausch + Lomb
- Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript
- Bausch + Lomb Corporation 2025 Q4 - Results - Earnings Call Presentation
- Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Bausch + Lomb reports mixed results; initiates FY26outlook
- Bausch + Lomb completes refinancing of outstanding term B loans
Read the full article on Seeking Alpha
For further details see:
Bausch + Lomb outlines 2026 revenue target of $5.475B with margin expansion driven by dry eye growth
Bausch + Lomb Corporation
NASDAQ: BLCO
BLCO Trading
1.85% G/L:
$17.35 Last:
60,308 Volume:
$17.10 Open:
BLCO Latest News
February 24, 2026 07:00:00 am
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
February 18, 2026 06:58:00 am
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
BLCO Stock Data
$6,074,354,796
39,385,904
0.1%
19
N/A
Medical Equipment & Supplies
Healthcare
CA
Vaughan
